Microbiome-Targeted Therapeutics in Immunology

  • ID: 4521257
  • Report
  • 78 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • 4D Pharma
  • Enterome Bioscience
  • Matrisys Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Synthetic Biologics
  • MORE
Microbiome-Targeted Therapeutics in Immunology

Summary

Flares in gastrointestinal and dermatology indications are characterized by a shift in the proportion of bacterial species in either the gut or skin microbiome. This report focuses on the development of therapies targeting the skin microbiome for the treatment of acne, atopic dermatitis and psoriasis and on the development of therapies targeting the gut microbiome for the treatment of Crohn’s disease, ulcerative colitis, and irritable bowel syndrome.

There are 10 pipeline therapies in clinical development (Phase I through Phase IIb/III) targeting the gut microbiome for the treatment of Crohn’s disease, UC, and IBS, while there are only three pipeline therapies in clinical development (Phase I through Phase III) targeting the skin microbiome for the treatment of acne, AD, and PsO.Currently, there are only three late-stage pipeline therapies targeting the microbiome in immunology - AOBiome’s Phase III B-244 for the treatment of acne, Synthetic Biologics’ Phase IIb/III SYN-010 (lovastatin MR) for the treatment of IBS-C, and Qu Biologics Phase IIB QBECO-SSI for Crohn’s disease.

Qu Biologics and AOBiome are the only two companies with microbiome-targeted therapeutics in both early- and late-stage development, but they are both banking on the success of the same drug, marking a substantial risk for these companies. Qu Biologics’ QBECO-SSI is in Phase IIb development for Crohn’s disease and Phase IIa development for UC, while AOBiome’s B-244 is in Phase III development for acne and Phase II development for AD.

The report "Microbiome-Targeted Therapeutics in Immunology", combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include:
  • Overview of the Gut and Skin Microbiome - microbial dysbiosis by indication
  • Epidemiology Overview - prevalent or diagnosed prevalent cases by indication for the 16MM
  • Pipeline Assessment-promising late-stage products and early-stage pipeline by indication
  • Key Players - leading industry companies by indication
  • Clinical Trials Mapping and Design - trial breakdown by phase/indication and trial design by indication
  • Fecal Microbiota Transplants-opportunities and challenges for gastrointestinal indications
  • Pricing, Reimbursement and Regulatory Strategy - US payer perspective on late-stage therapies
  • Market Outlook - market potential estimation of late-stage therapies and key launch dates
Companies mentioned in this report: Qu Biologics, Synthetic Biologics, 4D Pharma, Enterome Bioscience, Second Genome, Seres Therapeutics, Rebiotix, Intrexon, Vedanta Biosciences, AOBiome, Matrisys Bioscience and SFA Therapeutics

Scope

This report combines key opinion leader and payer insight with in-house analyst expertise to provide an insight-rich look at the microbiome space in immunology.

Components of the report include:
  • Overview of the Gut and Skin Microbiome: microbial dysbiosis by indication
  • Epidemiology Overview: prevalent or diagnosed prevalent cases by indication for the 16MM
  • Pipeline Assessment: promising late-stage products and early-stage pipeline by indication
  • Key Players: leading industry companies by indication
  • Clinical Trials Mapping and Design: trial breakdown by phase/indication and trial design by inidcation
  • Fecal Microbiota Transplants: opportunities and challenges for gastrointestinal indications
  • Pricing, Reimbursement and Regulatory Stategy: US payer perspective on late-stage therapies
  • Market Outlook: market potential estimation of late-stage therapies and key launch dates
Reasons to buy
  • Develop business strategies by understanding the trends shaping and driving the global microbiome market in immunology.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Gain insights to help plan and design your clinical trials.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
  • Identify key pricing and reimbursement strategies.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4D Pharma
  • Enterome Bioscience
  • Matrisys Bioscience
  • Rebiotix
  • Seres Therapeutics
  • Synthetic Biologics
  • MORE
1 Table of Contents

2. Executive Summary
2.1 Key Findings
2.2 KOL and Payer Insight on Microbiome Competitive Landscape

3. Overview of the Gut and Skin Microbiome
3.1 Microbiome of the Skin
3.2 Microbiome in Atopic Dermatitis
3.3 Microbiome in Acne
3.4 Microbiome in Psoriasis
3.5 Microbiome of the Gut
3.6 Microbiome in Inflammatory Bowel Disease
3.7 Microbiome in Irritable Bowel Syndrome

4. Epidemiology Analysis
4.1 Epidemiology Analysis - Acne Vulgaris
4.2 Epidemiology Analysis - Atopic Dermatitis
4.3 Epidemiology Analysis - Psoriasis
4.4 Epidemiology Analysis - Crohn’s Disease
4.5 Epidemiology Analysis - Ulcerative Colitis
4.6 Epidemiology Analysis - Irritable Bowel Syndrome

5. Pipeline Assessment
5.1 Overview of the Development of Pipeline Therapies
5.2 Pipeline Assessment - The Gut Microbiome
5.3 Qu Biologics’ QBECO-SSI
5.4 Synthetic Biologics’ SYN-010
5.5 Pipeline Assessment - The Skin Microbiome
5.6 AOBiome’s B-244
5.7 Matrisys Bioscience’s MSB-01

6. Key Players
6.1 Key Players - Companies Targeting the Microbiome
6.2 Analysis of Company Portfolio Gap - Gut Microbiome
6.3 Analysis of Company Portfolio Gap - Skin Microbiome

7. Clinical Trial Mapping and Design
7.1 Clinical Trial Mapping and Design - Gut Microbiome
7.2 Clinical Trial Mapping and Design - Skin Microbiome

8. Fecal Microbiota Transplants
8.1 Is Fecal Microbiota Transplant a Viable Option?
8.2 Clinical Trial Mapping and Design

9. Pricing, Reimbursement, and Regulatory Strategy
9.1 US Strategies for Gastrointestinal Indications
9.2 Payer Perspective on QBECO-SSI
9.3 Payer Perspective on SYN-010
9.4 US Strategies for Dermatology Indications
9.5 Payer Perspective on B-244
9.6 Payer Perspective on MSB-01

10. Market Outlook
10.1 Market Outlook for AOBiome’s B-244
10.2 Market Outlook for Synthetic Biologics’ SYN-010
10.3 Market Outlook for Qu Biologics’ QBECO-SSI
10.4 Key Launch Dates for Pipeline Therapies

11. Appendix
11.1 Sources
11.2 Methodology
11.3 Primary Research
11.4 About the Authors
11.5 About
11.6 Contact
11.7 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Qu Biologics
  • Synthetic Biologics
  • 4D Pharma
  • Enterome Bioscience
  • Second Genome
  • Seres Therapeutics
  • Rebiotix
  • Intrexon
  • Vedanta Biosciences
  • AOBiome
  • Matrisys Bioscience
  • SFA Therapeutics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll